Member Info for bignose58

Only until they reach the time limit restraint, then he will most likely sell out as will his mates.

I seriously would have thought Polina Mamoshina would have stated "when they first listed" since that is when they became an independent. Unless she meant they made a 300% profit in only a week !!!

At least for the DBC they used money out of the companies bank account, which, although lost and added weight to a dropping SP, shareholders still kept their original % holding. The DLI fiasco, however. used no company money and as such has so far cost investors 23% of their investment through a dilutionary (and delusionary) purchase. The DLI on the other hand, have had a 300% gain through the sale and award of shares in the company. !!! We have all been shafted good n proper.

Keith

That was my earlier point. The BOD and CEO don't have the ability to make proper investment decisions. They rely on someone else, who it would seem, historically, has no more interest in the private investor than Zebadee from the magic roundabout.... :-)

Someone posted this yesterday....

"Report in the Times today about China reducing length of time required for academic study to boost the birth rate"

We may certainly benefit from this, if true. Since our product aims to keep the goo in rather than out. It will be interesting to see if the testing still goes ahead/has a reduced number or participants or is accelerated....although you can not hurry a patient with the problem since the idea is to slllooowwww the process down....lol.

Anyway, food for thought ???

I see FFWD are disposing of their EMMAC shares due to some funny business going on with Yooma (formally Yooya). I've not read it all, but there seems to be some jiggery pokery going on there. Probably a good thing we never got involved ? ref announcement today and that on 11th Feb.....if anyone is interested. Is this yet another one involving JM ?

If anyone is interested.

The sell/buy ratio today was 11.9. the last time it was higher than this was on the 26th Nov last year at 21. The highest buy/sell ration was 10.4 on the 6th Oct.

The M&M's bought 9.33mill shares today (quite a lot compared to the other days) at an av sp of approx 0.197. I wonder why they would want to buy so many unless they see a possibly good upside ? And of course possibly filling gaps?

Morning The.Italian

The point I was making was whether the 20 dose had the same 9, 12 and 18 month stability requirements since shareholders were never advised on the matter. Yet we were on the 12 dose as they used it as an excuse for the eu launch delay.

Now that the 20 dose can is to be used for the us and poss China, I was wondering weather it had gone through the same rigorous testing, which from the linked document would seem to indicate it had.

Although it may not be important since it would seem it has followed the indicated protocol, it may have been yet another reason for FDA approval delay if it hadn’t and more so if they forgot about it, which is possible as they have forgotten to check many things before.

It would certainly appear the US requires it and since there is no mention of PRG/PLE performing the longer tests, It could indicate the 20 dose canister has already been shown to be stable for the periods in question?

Although I mention Recordati required it, which was the way it was put over in a shareholder announcement, As far as I can remember EU approval was given on 6 months since Recordati required it after the initial EU approval, however. That is not to say the 20 dose can didn't have it and it was just assumed the 12 dose can would exhibit the same result? The following linked document certainly suggests 9, 12 and 18 months are an EU requirement. see pages 1 and 4.

https://www.fda.gov/media/71707/download#:~:text=In%20general%2C%20this%20testing%20need,cover%20the%20proposed%20shelf%20life.

The. Italian,

As far as I am aware the impurities issues were solved a couple of months back (horses mouth and all that), however. That's isn't to say that some of the early batches cannot now be experiencing some issues. From what I remember, it was Recordati who requested the additional 9, 12 and 18month stability tests which further delayed the EU launch following the 6 dose debacle (wasn't EU approval based on only 6 months ?). I guess their initial thinking was that the product would sell quicker and were looking for a comfortable 12 months or less shelf life?

As I have mentioned many times before, greed is what has caused most of the delays. 20 dose to 6 dose to 12 dose and back to 20 dose. They should have continued with the 20 dose can from the beginning and looked at applying for a variation later which would have given them whatever time they needed to test a multitude of sizes whilst at the same time receiving an income. If they had done so, we would probably have had US, China and many more regions approvals by now, if not 6 months to a year ago. Instead, we are still waiting and ultimately the US will be using the 20 can as, I suspect from the content of the marketing report, will China (this is only based on the comment regarding US/China price differential).

Management needs to be replaced for allowing all this to happen, but instead. Some have actually been rewarded. WTF.

Dougie,

My reference to a couple of billion my seem at first excessive, however. If one considers the information contained within the US marketing announcement, its more likely a conservative figure.

They state that figures for ED are used as a basis which would appear to be considered as an accepted industry comparison. As such, if one just looks at the sales of the big 3 for ED (Cialis, Viagra, Levitra) which in 2019 according the March 2019 presentation had sales of (2.9Bill, 5.9Bill, 013Bill) respectively, giving total sales of 9Bill USD, which may be somewhat excessive, but even so 1 to 2 Billion USD could be considered chicken feed for something that could give a possible return of 10 billion or more over a period of say 5 to 7 years. And a lot more for a longer period.

Yes I am writing as if Fortacin has cornered the market, but currently there is no other drug anywhere like ours needing a prescrip for comparison. Maybe after 5 to 7 years there will be, but we dont really care what happens after that do we... ;-)

Of course if they decide to bring the EU sales into the equation, the above is totally flawed, however, It currently seems they appear to be ignoring this given the vastly different market and stigma attitudes.

Everyone can do their own math on the matter, but the above is pretty straightforward based on the information we have been provided.

As usual, only time will tell..............

Morning The.Italian,

Yes, you are positive towards the DLI investment which I salute you for. I'm afraid given the incompetence of the BOD before, I have no confidence until I see some positive business plan. Also, it would appear Dr Zoobidoo is spending more time promoting his own company InSilco and I wouldn't be surprised if he doesn't lose interest in the small fry due to there only being 24hrs in a day. I could be wrong as its just a feeling driven by historic events and abilities.

Heimdal,

It would translate to more that that since market cap would be be multiples until it settled down and they decided what to do with the dosh (use some for further investment and return the majority to shareholders), however. I think most would have sold out on the subsequent spike which could be 2 or 3 times that value.

However, this will only come about if the market research indicates possible yearly sales in the hundreds of millions which may prompt a licensee (apparently there are 7 or 8) to make an offer (hopefully a bidding war,,,,yums) if they agree on the figures. All speculation on my part, but maybe RPG will monitories the US for a lumpsum and keep a relatively good income for future use from China and other regions ??? Certainly would make logical sense if they want to start investing in other companies sooner than later.

I don't see much hope for the DLI since Insilico will be making what money there is to be made. I'm sure buying the DLI was to appease the HKSX regulation regarding RPG being an investment company (they have been lying and insinuating long enough that they have other investments) and track record of incompetence indicates it will eventually go a_rse up.

Next year (H2 2022) for China approval, if we are lucky and H2 2023 for the US. Hopefully the US prospective licensee buys the license for the US and Latin America for a billion or two before the end of this year so we can all jump ship.... one can but dream.

Bothwell,

They don't intend to sell the 12 dose can in the states. So the price is for the 20 dose can as is, I suspect, China given they made a comparison in price (1.5 times more in the US).

Seems to me the news about the OTC rollout in Europe is probably the catalyst for the drop since normally profit warnings have little to no impact (and this one is better tan normal). Are we now seeing a support level of around 0.2 to 0.21 ?

As Dougie wrote, more news to come in the next 6 months, so I'm sure once day traders start jumping back in again, it will lift the SP back to the dizzy heights of 0.25 or even "Infinity and beyond"...lol This may indeed start after the YE results are uploaded since they have also stated "Further operational information will be contained in the Company’s final annual results announcement".

We will see, although I still don't understand why no mention of the 4millUSD receipt was mentioned, even to say it was delayed?

As I wrote before. Probably just another DBC. The BOD have no clue on how to run a business. And I will continue to believe that until I see some proper business etiquette to indicate they have an inkling of what they are doing.

Heimdal,

You’ve certainly changed your tune a bit.

Look back and see when the previous years reports were uploaded.